Christopher Robert Bebbington

This inventor holds 44 USPTO granted patents and 26 published patent applications, plus 4 CIPO patents and 17 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Kalobios Pharmaceuticals, Inc., Medarex Inc., Oxford Biomedica (UK) Limited. Active years: 2004-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Christopher Robert Bebbington. Retrieved from https://idiyas.com/inventor/christopher-robert-bebbington

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 44 (Patent Applications = 26)

% Patents Active = 54.5

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 17 (Patent Applications = 14)

Average Co-Inventor Count = 4.1

ph-index = 8

Forward Citations = 274(Granted Patents)

Location History:

Berkshire, GB (2004 - 2007)
Oxford, CA (US) (2007)
Newbury, GB (2009)
South San Francisco, CA (US) (2006 - 2015)
San Mateo, CA (US) (2005 - 2021)
San Carlos, CA (US) (2023 - 2024)

Company Filing History:

16 out of 19

Kalobios Pharmaceuticals, Inc.

Oxford Biomedica (UK) Limited

Oxford Biomedica, Inc.

patents

6. 1 out of 389

Beijing University of Technology

Ludwig Institute for Cancer Research Limited

patents

where one patent can have more than one assignee

Years Active: 2004-2024

Loading Chart...

Areas of Expertise:

Anti-Siglec-7

EphA3 Antibodies

Cancer Treatment

Fibrotic Diseases

Allergic Conjunctivitis

Signal Peptides

GM-CSF Antagonist

Hematological Disorders

Therapeutic Antibodies

Dementia Treatment

Prodrug Compounds

Transactivation System

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11912766 - Anti-Siglec-7 antibodies having reduced effector function (2024-02-27),

2. 11773162 - Anti-Siglec-7 antibodies for the treatment of cancer (2023-10-03),

3. 11203638 - Methods and compositions for treating perennial allergic conjunctivitis and keratoconjunctivitis (2021-12-21),

4. 10919983 - Immunoglobulin variable region cassette exchange (2021-02-16),

5. 10774145 - Methods and compositions for treating fibrotic diseases (2020-09-15),

6. 10604577 - Methods and compositions for treating systemic mastocytosis (2020-03-31),

7. 10183996 - Methods and compositions for treating Siglec-8 associated diseases (2019-01-22),

8. 9546215 - Anti-Siglec-8 antibodies and methods of use thereof (2017-01-17),

9. 9290571 - Antibodies to EphA3 (2016-03-22),

10. 9127046 - Secretion of antibodies without signal peptides from bacteria (2015-09-08),

11. 9109032 - Methods of treating hematological proliferative disorders by targeting EphA3 expressed on aberrant vasculature in bone marrow (2015-08-18),

12. 9045539 - Anti-EMR1 antibodies (2015-06-02),

13. 9017674 - Antibodies to granulocyte-macrophage colony-stimulating factor (2015-04-28),

14. 8877191 - [object Object] (2014-11-04),

15. 8834870 - Treatment of leukemias and chronic myeloproliferative diseases with antibodies to EphA3 (2014-09-16),

Title: Christopher Robert Bebbington: Innovator in Cancer Treatment

Introduction

Christopher Robert Bebbington is a prominent inventor based in San Mateo, California, known for his significant contributions to cancer treatment through the development of innovative antibody therapies. With an impressive portfolio of 44 patents, Bebbington has dedicated his career to advancing medical science and improving patient outcomes.

Latest Patents

Among his latest inventions are the "Anti-Siglec-7 antibodies having reduced effector function" and "Anti-Siglec-7 antibodies for the treatment of cancer." These patents provide novel methods and compositions that demonstrate potential in treating cancer by utilizing anti-Siglec-7 antibodies, paving the way for transformative therapies in oncology.

Career Highlights

Bebbington has held key positions at notable companies such as KaloBios Pharmaceuticals, Inc. and Medarex, Inc., where he has been instrumental in the development of cutting-edge therapeutic solutions. His extensive experience in biotechnology has made him a critical player in the field of biomedical innovations.

Collaborations

Throughout his career, Bebbington has collaborated with renowned professionals, including Geoffrey T. Yarranton and Susan Mary Kingsman. These partnerships have allowed him to leverage diverse expertise and drive forward-thinking projects that aim to revolutionize cancer treatment.

Conclusion

Christopher Robert Bebbington exemplifies the spirit of innovation in the biomedical field. His dedicated work and substantial patent portfolio reflect his commitment to advancing cancer therapies, showcasing the impact of collaboration and creativity in achieving medical breakthroughs. As he continues to push the boundaries of research, Bebbington remains a pivotal figure in the fight against cancer.

Profile summary based on public USPTO records.